India's Sun Pharma gets FDA import ban on Gujarat plant
MUMBAI, March 13 (Reuters) - The United States Food and Drug Administration (FDA) has imposed an import alert, effectively a ban, on Indian generic drugmaker Sun Pharmaceutical Industries Ltd's plant in the western Indian state of Gujarat.
An "import alert" results in the detention without physical examination of drugs from firms that have not met so-called good manufacturing practices, according to the FDA website.
A spokesman for Sun, India's biggest drugmaker by market value, was not available for comment.
The plant in Karkhadi in Gujarat makes both drug ingredients and formulations, according to Sun's 2013 annual report.
Terms and Privacy Policy